MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience. "I am thrilled to continue working ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Rachel Vatnsdal - JPMorgan Ricki Levitus - Guggenheim Vivian Bais - BTIG Tim Cheung - Capital One Mason Carrico - Stephens Oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Dela ...

● For the second quarter of 2024, revenue was $23.2 million, a 26.2% quarter- over-quarter increase from $18.4 million in the first quarter and 1.5% year-over- year decrease from $23.5 million in the second quarter of 2023. o Instruments, consumables and services all contributed to sequential growth. Instrument revenue was $8.3 million, a 70.4% quarter-over- quarter increase. Reagent revenue was $7.4 million, a 5.6% quarter- over-quarter increase. Service and other revenue was $7.2 million, a 16.6% quarter- ...

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A ...

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A ...

nicolas_Introduction I believe one of the best sectors of the healthcare industry is the Lab Instrument and Services providers who can generate high recurring revenues from small amounts of instrument sales. Examples include research focused Thermo Fisher (TMO) and Danaher (DHR), along with diagnostics providers such as Qiagen (QGEN) and Revvity (RVTY). I have discussed the opportunity in these names recently as the healthcare industry is facing immense headwinds not seen since major recessions. As such ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Kyle Mikson - Canaccord David Westenberg - Piper Sandler Mark Massaro - BTIG Tejas Savant - Morgan Stanley Subhalaxmi Nambi - Guggenheim Rachel Vatnsdal - JP Morgan Mason Carrico - Stephens Timothy Chiang - Capital One Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Firs ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this tissue analysis provider would post a loss of $0.27 per share when it actually produced a loss of $0.22, delivering a surprise of 18.52%.Over the last four quarters, the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Del ...